Ignite Creation Date:
2025-12-24 @ 7:35 PM
Ignite Modification Date:
2025-12-25 @ 5:16 PM
Study NCT ID:
NCT06731803
Status:
RECRUITING
Last Update Posted:
2025-04-02
First Post:
2024-12-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-03-25
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-09
First Submit QC Date:
None
Study First Post Date:
2024-12-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-28
Last Update Post Date:
2025-04-02
Last Update Post Date Type:
ACTUAL